OCEAOTCPharmaceutical PreparationsFiscal year ends December 31

Ocean Biomedical, Inc.

Financials through Q1 FY2025, quarter ended Mar 31, 2025Last filing: 10-Q on May 15, 2025

$0.00−0.00 (-16.67%)

Close on Oct 19, 2026

Market cap: $45.51K
P/E (TTM): –
Dividend yield: –

Ocean Biomedical, Inc. cash flow statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Stock-Based Compensation	0.75	1.21	12
Change in Accounts Payable	0.87	1.23	2.81
Operating Cash Flow	-4.18	-9.43	-0.99
Purchase of Investments	–	–	-2.10
Investing Cash Flow	–	–	-2.10
Stock Issued	–	14	–
Debt Issued	–	–	2.10
Taxes Paid on Share-Based Awards	–	-13	–
Financing Cash Flow	3.40	10	0.97
Net Change in Cash	-0.78	0.97	-0.03

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2025

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2024: 10.1%

Financial strength

Current ratio: 0.06
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 3.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –